Vaccines against sexually transmitted infections: The way forward

Vaccine

Volumn 32, Issue 14, 2014, Pages 1630-1637

  Broutet, Nathalie ^a   Fruth, Uli ^a   Deal, Carolyn ^b   Gottlieb, Sami L ^a   Rees, Helen ^c  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; CHLAMYDIA VACCINE; GONORRHEA VACCINE; HERPES SIMPLEX VACCINE; SYPHILIS VACCINE; TRICHOMONIASIS VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; GONORRHEA; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HUMAN; NEISSERIA GONORRHOEAE; NONHUMAN; NOTE; PRIORITY JOURNAL; SEXUALLY TRANSMITTED DISEASE; SYPHILIS; TREPONEMA PALLIDUM; TRICHOMONAS VAGINALIS; TRICHOMONIASIS; VACCINATION;

BIOMEDICAL RESEARCH; HEALTH POLICY; HUMANS; INTERNATIONAL COOPERATION; PRIVATE SECTOR; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; RESEARCH DESIGN; SEXUALLY TRANSMITTED DISEASES; VACCINES;

EID: 84896711413     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.01.053     Document Type: Note

References (38)

1. Global Vaccine Action Plan 2011-2020. http://www.who.int/immunization/global_vaccine_action_plan/GVAP_doc_2011_2020/en/index.html.
2. WHO/UNAIDS HIV vaccine initiative calls for accelerated research to build on trial accomplishments. Wkly Epidemiol Rec 2003, 78(9):62-63.
3. Looker K.J., Garnett G.P., Schmid G.P. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ 2008, 86(10):805-812. A.
4. Freeman E.E., Weiss H.A., Glynn J.R., Cross P.L., Whitworth J.A., Hayes R.J. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006, 20(1):73-83.
5. Johnston C., Koelle D.M., Wald A. Current status and prospects for development of an HSV vaccine. Vaccine 2014, 32:1553-1560.
6. Stanberry L.R., Spruance S.L., Cunningham A.L., Bernstein D.I., Mindel A., Sacks S., et al. Glycoprotein-d-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002, 347(21):1652-1661.
7. Belshe R.B., Leone P.A., Bernstein D.I., Wald A., Levin M.J., Stapleton J.T., et al. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 2012, 366(1):34-43.
8. World Health Organization Global incidence and prevalence of selected curable sexually transmitted infections - 2008 2012, World Health Organization, Geneva. http://apps.who.int/iris/bitstream/10665/75181/1/9789241503839_eng.pdf.
9. Gottlieb S.L., Low N., Newman L.M., Bolan G., Kamb M., Broutet N. Toward global prevention of sexually transmitted infections (STIs): the need for STI vaccines. Vaccine 2014, 32:1527-1535.
10. Hafner L.M., Wilson D.P., Timms P. Development status and future prospects for a vaccine against Chlamydia trachomatis infection. Vaccine 2014, 32:1563-1571.
11. Mabey D.C.W., Hu V., Bailey R.L., Burton M.J., Holland J. Towards a safe and effective chlamydial vaccine: lessons from the eye. Vaccine 2014, 32:1572-1578.
12. Bagnoli F., Baudner B., Mishra R.P., Bartolini E., Fiaschi L., Mariotti P., et al. Designing the next generation of vaccines for global public health. OMICS 2011, 15(9):545-566.
13. Wang Y., Kahane S., Cutcliffe L.T., Skilton R.J., Lambden P.R., Clarke I.N. Development of a transformation system for Chlamydia trachomatis: restoration of glycogen biosynthesis by acquisition of a plasmid shuttle vector. PLoS Pathog 2011, 7(9):e1002258.
14. Kari L., Whitmire W.M., Olivares-Zavaleta N., Goheen M.M., Taylor L.D., Carlson J.H., et al. A live-attenuated chlamydial vaccine protects against trachoma in nonhuman primates. J Exp Med 2011, 208(11):2217-2223.
15. Gray R.T., Beagley K.W., Timms P., Wilson D.P. Modeling the impact of potential vaccines on epidemics of sexually transmitted Chlamydia trachomatis infection. J Infect Dis 2009, 199(11):1680-1688.
16. World Health Organization Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae 2012, World Health Organization, Geneva. http://whqlibdoc.who.int/publications/2012/9789241503501_eng.pdf.
17. Jerse A.E., Bash M.C., Russell M.W. Vaccines against gonorrhea: current status and future challenges. Vaccine 2014, 32:1579-1587.
18. Serruto D., Bottomley M.J., Ram S., Giuliani M.M., Rappuoli R. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine 2012, 30(Suppl. 2):B87-B97.
19. Gulati S., Zheng B., Reed G.W., Su X., Cox A.D., Michael S.T.F., et al. Immunization against a saccharide epitope accelerates clearance of experimental gonococcal infection. PLoS Pathog 2013, 9(8):e1003559. 10.1371/journal.ppat.1003559.
20. Hobbs M.M., Sparling P.F., Cohen M.S., Shafer W.M., Deal C.D., Jerse A.E. Experimental gonococcal infection in male volunteers: cumulative experience with Neisseria gonorrhoeae strains FA1090 and MS11mkC. Front Microbiol 2011, 2:123. 10.3389/fmicb.2011.00123.
21. Smith J., Garber G. Current status and prospects for development of a vaccine against Trichomonas vaginalis infections. Vaccine 2014, 32:1588-1594.
22. Stark J.R., Judson G., Alderete J.F., Mundodi V., Kucknoor A.S., Giovannucci E.L., et al. Prospective study of Trichomonas vaginalis infection and prostate cancer incidence and mortality: physicians' health study. J Natl Cancer Inst 2009, 101:1-6.
23. Ginocchio C.C., Chapin K., Smith J.S., Aslanzadeh J., Snook J., Hill C.S., et al. Prevalence of Trichomonas vaginalis and coinfection with Chlamydia trachomatis and Neisseria gonorrhoeae in the United States as determined by the Aptima Trichomonas vaginalis nucleic acid amplification assay. J Clin Microbiol 2012, 50(8):2601-2608.
24. Centers for Disease Control and Prevention Sexually transmitted disease surveillance 2011 2012, US Department of Health and Human Services, Atlanta. http://www.cdc.gov/std/stats11/Surv2011.pdf.
25. European Centre for Disease Prevention and Control Sexually transmitted infections in Europe 1990-2010 2012, ECDC, Stockholm. http://www.ecdc.europa.eu/en/publications/Publications/201206-Sexually-Transmitted-Infections-Europe-2010.pdf.
26. Newman L., Kamb M., Hawkes S., Gomez G., Say L., Seuc A., et al. Global estimates of syphilis in pregnancy and associated adverse outcomes: analysis of multinational antenatal surveillance data. PLoS Med 2013, 10(2):e1001396.
27. Murray C.J., Vos T., Lozano R., Naqhavi M., Flaxman A.D., Michaud C., et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380(9859):2197-2223.
28. Hawkes S., Matin N., Broutet N., Low N. Effectiveness of interventions to improve screening for syphilis in pregnancy: a systematic review and meta-analysis. Lancet Infect Dis 2011, 11(9):684-691. 10.1016/S1473-3099(11)70104-9.
29. Garnett G.P. The theoretical impact and cost-effectiveness of vaccines that protect against sexually transmitted infections and disease. Vaccine 2014, [in this issue].
30. Cameron C.E., Lukehart S.A. Current status of syphilis vaccine development: need, challenges, prospects. Vaccine 2014, 32:1602-1609.
31. UNAIDS. Global AIDS Response Progress Reporting. [accessed 22.11.13]. http://www.unaids.org/en/dataanalysis/knowyourresponse/globalaidsprogressreporting/.
32. Cates W., Farley T.M., Rowe P.J. Worldwide patterns of infertility: is Africa different?. Lancet 1985, 2(8455):596-598.
33. World Health Organization Reproductive health strategy to accelerate progress towards the attainment of international development goals and targets 2004, World Health Organization, Geneva. http://whqlibdoc.who.int/hq/2004/WHO_RHR_04.8.pdf.
34. United Nations Secretary General Global strategy for women's and children's health. The partnership for maternal, newborn and child health 2010, http://www.who.int/pmnch/topics/maternal/201009_globalstrategy_wch/en/ [accessed 08.11.13].
35. Decade of Vaccines. [accessed 08.11.13]. http://www.dovcollaboration.org/.
36. Alonso PL, de Quadros CA, Lal AA, editors. Decade of vaccines. Vaccine 2013;31(Suppl. 2):B1-B249.
37. Frasch C.E., Preziosi M.P., LaForce F.M. Development of a group A meningococcal conjugate vaccine, MenAfrica™. Hum Vaccin Immunother 2012, 8(6):715-724.
38. Bishai D.M., Champion C., Steele M.E., Thompson L. Product development partnerships hit their stride: lessons from developing a meningitis vaccine for Africa. Health Aff 2011, 30(6):1058-1064.